ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

NCCS Networker Volume 8 Issue 3, Fall 1994

September 12, 1994

NCI Programs: Genetic Variations Discovered, Added to NCI Database

June 11, 1999

In Brief: NCCR Presents Gold Medal To Sen. Karkin; DCT Recruits Okunieff For Radiation Oncology

February 26, 1993

U.S. Radiologists Criticize Canadian Study Of Mammography Screening Showing No Benefit

November 27, 1992

In Brief: Albert and Mary Lasker Foundation announce 2014 award winners

September 12, 2014

In Brief: Broder Invokes Cancer Act Provision To Inform Hammer, Bush Of Potential Damage Of 32% Cut

September 7, 1990